We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+70.52%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$500M
AUM Growth
+$238M
Cap. Flow
+$169M
Cap. Flow %
33.67%
Top 10 Hldgs %
50.21%
Holding
73
New
32
Increased
7
Reduced
5
Closed
27

Top Buys

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$55.5M
2
RNAM
Avidity Biosciences
RNAM
+$26.7M
3
RPTX
Repare Therapeutics
RPTX
+$21.4M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$17.9M
5
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$16.8M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$20.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$18.3M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$14.1M
4
MRNA icon
Moderna
MRNA
+$13.8M
5
ASND icon
Ascendis Pharma A/S
ASND
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 95.61%
2 Miscellaneous 4.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
51
DELISTED
Blueprint Medicines
BPMC
– –
-75,000
Closed -$4.39M
CRSP icon
52
CRISPR Therapeutics
CRSP
$5.54B
– –
-105,512
Closed -$4.47M
FATE icon
53
Fate Therapeutics
FATE
$302M
– –
-193,144
Closed -$4.29M
FOLD
54
DELISTED
Amicus Therapeutics
FOLD
– –
-446,882
Closed -$4.13M
IOVA icon
55
Iovance Biotherapeutics
IOVA
$4.54B
– –
-247,248
Closed -$7.4M
MRNA icon
56
Moderna
MRNA
$63.1B
– –
-460,000
Closed -$13.8M
NERV icon
57
Minerva Neurosciences
NERV
$165M
– –
-38,718
Closed -$1.86M
RNAC icon
58
Cartesian Therapeutics
RNAC
$238M
– –
-37,062
Closed -$2.68M
RVMD icon
59
Revolution Medicines
RVMD
$42.2B
– –
-53,034
Closed -$1.16M
SAGE
60
DELISTED
Sage Therapeutics
SAGE
– –
-69,591
Closed -$2M
SRPT icon
61
Sarepta Therapeutics
SRPT
$2.18B
– –
-187,350
Closed -$18.3M
SVRA icon
62
Savara
SVRA
$1.11B
– –
-613,999
Closed -$1.17M
TXG icon
63
10x Genomics
TXG
$10B
– –
-72,831
Closed -$4.54M
VRTX icon
64
Vertex Pharmaceuticals
VRTX
$131B
– –
-33,237
Closed -$7.91M
VSTM icon
65
Verastem
VSTM
$684M
– –
-193,799
Closed -$5.53M
ZYME icon
66
Zymeworks
ZYME
$1.97B
– –
-304,417
Closed -$10.8M
KRTX
67
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-69,658
Closed -$5.01M
MRTX
68
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-33,300
Closed -$2.56M
MRTX
69
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-46,399
Closed -$3.57M
MTEM
70
DELISTED
Molecular Templates, Inc.
MTEM
– –
-29,255
Closed -$5.83M
TRIL
71
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-995,600
Closed -$4.02M
MYOK
72
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-300,000
Closed -$14.1M
IMMU
73
DELISTED
Immunomedics Inc
IMMU
– –
-276,635
Closed -$3.73M
1 2
3

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q2 2020 Portfolio in Review

As of Q2 2020, Logos Global Management held 73 positions worth $500M, up 90% from $263M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Logos Global Management deployed $169M of net new capital in Q2 2020, opening 32 new positions and adding to 7 existing holdings. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 1,280,000 shares worth $59.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Passage Bio, an estimated $5.82M trimmed.

  • Logos Global Management's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 1,280,000 shares worth $59.5M.
  • Logos Global Management added most to Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020, an estimated $17.9M increase.
  • Logos Global Management's biggest Q2 2020 reduction was Passage Bio, cutting an estimated $5.82M.
  • Logos Global Management fully exited AbbVie in Q2 2020, selling an estimated $20.2M.
  • Logos Global Management's ten largest holdings make up 50% of its $500M portfolio in Q2 2020.
  • Logos Global Management opened 32 new positions and closed 27 in Q2 2020.
  • Logos Global Management's portfolio value rose 90% quarter-over-quarter to $500M.

Based on Logos Global Management's 13F filing for Q2 2020, filed 14 Aug 2020.